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Editorial
Implantable Device Prescription in 2004: A Complex Business?
CHU-PAK LAU
From Cardiology Division, The University of Hong Kong, Queen Mary Hospital, Hong Kong

Implantable devices are now used to treat
patients with congestive heart failure (CHF) with
electromechanical in dyssynchrony. 1-4 The proven
benefits include improvement in cardiovascular
functional state such as better exercise capacity,
6 min-hallwalk distance, New York Heart
Association Class and quality of life. There is also
measurable structural change in reverse left
ventricular (LV) remodelling. 5 These lead to
combined clinical benefit of reduced hospitalisation
and possibly reduced mortality. On the other hand,
patients with CHF has a high risk of concomitant
arrhythmias, and sudden cardiac death is an important
cause of mortality in these patients. 6 Prophylactic
implantable cardioverter defibrillator (ICD) has been
shown to improve survival over best medical therapy
when implanted either for primary or secondary
prevention. 7-8 Thus when a device is prescribed for
any patients, one must consider these therapeutic
options so that the patient can derive the maximum
benefit from an optional device. Upgrading a device
is not only costly, but can be difficult because of
access issues and complexity of multiple leads.

Congestive Heart Failure
In patients with a QRS >120 ms and poor
ejection fraction (EF, <35%), cardiac
resynchronisation therapy (CRT) is now a Class IIa
indication for pacing. The main argument here is
whether to use a CRT or a CRT with ICD backup
(CRT-D) in the CHF population with high risk of
SCD. 9 The pros would advocate a one-off device
treatment which is evidenced based 8-9 both for
ischaemic and non-ischaemic cardiomyopathy. In
addition, most benefits of ICD are in patients with
wide an underlying QRS complex. The antagonist
would argue the relative small benefit of ICD over
drug therapy (e.g. 106 vs 97 deaths in the drug vs
ICD arms in MADIT 2). In addition, many CHF
patients have significant co-morbidities that would
limit the lifespan of these individuals, and CRT alone
would give good clinical relief and reduce
hospitalisation. Cost is an important issue in all
countries. In patients with narrow QRS complex,
underlying LV dyssynchrony may be present, and
these patients may also benefit from CRT, although
we do not yet have trial data.

Bradycardia Pacing
Address for reprints: Prof. Chu-Pak Lau
Chief of Cardiology Division (Academic), The University of Hong
Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong
Fax: (852) 2818 6304
Opinions expressed are views of the authors and not necessarily
the view of the editorial board or the Hong Kong College of
Cardiology.
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Existing studies with the exception of a
proportion of patients in MUSTIC1 do not include a
group of patients with right ventricular (RV) pacing,
which induces a wide QRS complex. Whether one
can extrapolate existing short to intermediate
term data to these patients remain controversial
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particularly for patients – who are not symptomatic
of heart failure. For patients with sick sinus
syndrome, it may be fair to apply the current
indication for CRT in these patients if conconcomitant LBBB and CHF are present. In patients
with complete atrioventricular (AV) block, the
situation is a little more complex. A LV based pacing
system after AV nodal ablation gives a better acute
haemodynamic results compared to RV pacing. 10
There is less mitral regurgitation and better ejection
fraction after LV pacing compared to RV pacing. The
data also suggest similar benefit in patients with
either preserved or impaired EF. These data have
implication of the use of CRT rather than RV pacing
after AVN ablation. There is as yet no data for
idopathic AV block. Whether one should implant a
CRT device in AV block remains controversial and
it is uncertain if a CRT-D should be used in those
with poor EF. RV apical pacing is associated with
long term impairment of LV function and regional
perfusion defects, and RV septal pacing may be an
alternative way to preserve LV function.11

Conclusion
We are now at a crossroad when prescribing a
device for a patient with combination of brady or
tachyarrhythmias with poor LV function. For most
patients, a single, most sophisticated device that fit
all purpose is clearly appealing, but there are issues
in risk of procedure, cost and complexity in
programming. We clearly need data to best tailor
therapy for the individual patient to minimize the
need for system change, and yet medically, socially,
and economically acceptable.

2
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Two Cases of Long-term Coronary Sinus Pacing by Medtronic
Model 6992 Lead
YUJI NAKAZATO1 AND YASURO NAKATA2
From 1Division of Cardiology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo
and 2Department of Cardiology, Juntendo Izu-Nagaoka Hospital, Shizuoka, Japan
NAKAZATO and NAKATA: Two Cases of Long-term Coronary Sinus Pacing by Medtronic Model 6992 Lead.
In late '70s, coronary sinus (CS) pacing was clinically performed by using several specifically designed lead systems.
However, there is scant long-term follow-up data covering periods more than 15 years. We report two patients with
sick sinus syndrome in whom CS pacing with Medtronic model 6992 lead system was successfully applied for 17 and
21 years, respectively. (J HK Coll Cardiol 2004;12:3-6)
Left atrial pacing, pacing lead, prognosis, sick sinus syndrome

6992

21

Introduction
Coronary sinus (CS) is an optional site for atrial
pacing if an optimal site cannot be found in the right
atrium. Although lead dislodgement and/or threshold
rise were observed in limited cases, the long-term
feasibility of the CS pacing method by standard or
specifically designed lead systems has been reported.1,2
However, no follow-up data over 15 years using
Medtronic model 6992 CS lead has been reported. We

Address for reprints: Dr. Yuji Nakazato
Division of Cardiology, Department of Internal Medicine,
Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyoku, Tokyo 113-8421, Japan
Tel: (81) 3-3813-3111, Fax: (81) 3-5689-0627
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have experienced two patients with sick sinus
syndrome (SSS) in whom CS pacing by this system
was successfully implanted at late '70 and applied
for 17 and 21 years, respectively.

Case Reports
Case 1
The patient was a 77-year-old male with SSS.
At the age of 55, he was implanted with an AAI mode
pacemaker using a Medtronic model 6992 CS lead
(Figures 1a & 1b). Unipolar pacing was performed
because of better thresholds than bipolar pacing. The
voltage (V) and current (mA) thresholds measured
with a pulse width of 0.6 msec were 2.4 V and 7.9
mA respectively at the time of implantation. P-wave
amplitude was 2.1 mV and pacing impedance was
304 ohms. Although two generator changes were
performed at 8 and 12 years following initial implant,
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these parameters remained stable (Table 1).
Thereafter, CS pacing was successfully performed
for 17 years until lead fracture was found at the
vicinity of puncture site. We abandoned the CS lead

(a)

and implanted a new pacing system from the opposite
site. ECG during CS pacing has not changed and no
progression to atrioventricular block was noted
(Figure 1c).

(b)

(c)

Figure 1. Chest X-ray and ECG in Case 1. (a & b) CS
lead is clearly recognizable in the Postero-anterior
and lateral projections. (c) ECG showed stable atrial
pacing. New pacing system implanted after CS lead
fracture is seen at opposite site.

Table 1. Change of measurements at the time of initial implantation and replacement in Case 1
Initial implant

Voltage* (V)
Current* (mA)

('78)
2.4
7.9

1st
('85)
3.2
9.6

Replacement
2nd
('90)
2.2
5.6

P-wave (mV)
Impedance (Ω)

2.1
304

1.8
315

2.4
379

3rd
('95)
fracture
0.3
740

*Measured at pulse width of 0.6 ms

4
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Case 2
The patient was a 68-year-old female with SSS.
At the age of 48, she had recurrent syncope due to
sinus arrest and CS pacing with a Medtronic 6992
lead was performed (Figures 2a & 2b). At the time
of initial implantation, the voltage and current
thresholds measured at a pulse width of 0.6 msec were
1.2 V and 2.8 mA respectively, and P-wave amplitude
was 3.7 mV all in the unipolar configuration.
Subsequently, the lead remained functional after one
generator change with the last measured thresholds
of 1.3 V and 2.9 mA at 0.6 ms, a P-wave amplitude
of 2.6 mV and lead impedance of 540Ω. Stable CS
pacing has been maintained for 21 years since the
initial implantation. Voltage threshold during the
follow-up period has ranged from 1.8 V to 2.2 V with
a pulse width of 0.5 msec. The ECG has indicated

(a)

constant AAI pacing and no progression to
atrioventricular block is noted during the follow-up
period (Figure 2b).

Discussion
Recent advances in pacing lead technology
have made stable atrial pacing possible. The prevalent
lead fixation sites are the right atrial free wall by
screw-in leads or the right atrial appendage by
J-shaped leads. CS is another optional site for atrial
pacing and several specially designed CS leads were
used before the development of above two lead
systems.1,2 However, the CS lead has the concern of
lead dislodgement and/or threshold rise and their
clinical application was very limited.1-3

(b)

(c)

Figure 2. Chest X-ray and ECG in Case 2. (a & b) CS
lead is clearly recognizable in the Postero-anterior and
lateral projection. (c) ECG showed stable atrial pacing.
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Moss and Rivers2 reported ten-year experience
in 50 patients with CS pacing by Medtronic model 5818
and 6904 bipolar pacing lead. They had 11 electrode
related malpacing events, or a rate of 10% in the first
pacing month, 1.1% per paced month during the next
six months, and 0.25% per paced month thereafter.
Within 7 months, they observed lead dislodgement and
high thresholds as major problems. Effective atrial
pacing was achieved in 76% of the patients during a
follow-up of more than five years. They concluded that
long term atrial pacing from the CS was safe and
effective.
Greenberg et al1 reported 66 patients with CS
pacing by specifically designed leads. During an average
follow-up of 14 months the failure rate was 14% and
they reported 4 cases of lead dislodgement and 4 cases
of threshold rise.
In the present cases, we had a chance to use
Medtronic 6992 leads for CS pacing. Until then, we
had no means of atrial pacing for sic sinus syndrome.
This lead has a straight tapered tip with bipolar
electrodes for obtaining stable fixation. However,
unipolar use with distal electrode provides superior
thresholds as compared to bipolar use. This could be
explained by the fact that proximal electrode more
mobile and could not maintain good contact with
surrounded CS tissues. Ideally, it had been better to fix
the lead in optimal position for good thresholds.
However, if this CS lead was once fixed, it could not be
changed the position for preventing dislodgement. If
the thresholds were not acceptable at this position, we
might have abondoned it and obliged to chose
ventricular pacing. In our 2nd case, voltage and current
thresholds were 1.3 V and 2.9 mA respectively. These
were similar to Greenberg et al's1 and Moss and Rivers's2

6

reports which stated an overall average threshold by
unipolar and bipolar CS pacing as 2.3 mA in both series.
Relatively high thresholds were obtained in our 1st case,
but they were mostly stable. Thus, the thresholds during
long-term follow-up periods were acceptable and lead
dislodgement was not observed in either cases.
Recently, the indication of biatrial pacing is
emphasized for the prevention of refractory atrial
tachyarrhythmias. 4 In such cases, CS pacing is a
necessary site for left atrial pacing. Therefore, the longterm prognosis of CS leads is major concern. Rosenthal
and Cook reported that significant adhesions to the
coronary veins were found 12 years after placing a
pacing lead in the posterolateral coronary vein.5 The
results of their observation and the presented cases
support that the long-term CS pacing is feasible with
safety. It may encourage selecting the CS as a site for
multisite pacing if it is needed.
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Surgery for Cardiac Tumors (Primary and Secondary) – Clinical
Experience and Surgical Results in 22 Patients: Queen Elizabeth
Hospital
KAR-WAI LAM,1 CHAN-CHUNG MA,1 KWOK-KEUNG HO,1 CHEUNG-WAH CHENG,2 KAM-TIM CHAN2
From 1Department of Cardiothoracic Surgery; 2Cardiology Division, Department of Medicine, Queen Elizabeth
Hospital, Hong Kong
LAM ET AL.: Surgery for Cardiac Tumors (Primary and Secondary) – Clinical Experience and Surgical Results
in 22 Patients: Queen Elizabeth Hospital. Purpose: Retrospective review of surgical management of the 22 cardiac
tumors resected in Queen Elizabeth Hospital during the period of March 1995-December 2002. Methods: Presenting
symptoms, diagnostic data, anatomical findings, surgical techniques, morbidity and complications of surgery were
recorded. Follow up data was retrieved from out-patient records. Results: There were 12 male (54.5%) and 10
female (45.4%) patients. Median age was 61. 50% (11/22) of the cases were myxoma. Of the remaining cases, 27.3%
(6/22) were various types of secondary metastastic tumor, 13.6% (3/22) were tumor of mediastinum with cardiac
invasion, and 9.1% (2/23) were primary malignancy. Left sided masses were dominated by myxoma, which were
sited either on the inter-atrial septum (81.8%) or left atrium (18.1%). All other tumor groups were found on the right
side. Dyspnea (81.9%) was the most common presenting symptom, followed by chest pain (31.8%), embolic events
(13.6%) and superior vena cava obstruction. All tumors were resected with cardiopulmonary bypass under moderate
hypothermia, undertaken via either right atriotomy, superior septal and trans-septal with full thickness excision. The
average cross-clamp time and bypass time were 48.6 minutes and 101.4 minutes respectively. The average blood
loss was 813 ml. Post-operatively, 2 of the cases were complicated by junctional bradycardia and one of them
required permanent pacing. Other complications including pericardial effusion, superior vena cava obstruction,
pneumonia, secondary hemorrhage had been reported. The average follow up period was 40 months ranging from
3 months to 8 years. All patients with primary benign myxoma remained asymptomatic except one died 3 years after
surgery. This patient had known co-existing history of breast cancer. She suffered from embolic complications and
finally succumbed from multiple organ failure. All patients with secondary neoplasms died during the course of
follow-up. One with germ cell tumor was lost to follow up. Survival for primary benign tumors and cardiac metastasis
from secondary tumors, were 34 and 6 months respectively. The median survival of all tumors was 25 months.
Surgical resection, when possible, is the treatment of choice for all patients with cardiac neoplasms. It is curative in
benign tumors. On the other hand, palliative surgical procedures may be carried out for malignant tumors for relief
of obstructive symptoms and allow time for adjuvant therapy. (J HK Coll Cardiol 2004;12:7-15)
Cardiac tumor, myxoma, superior septal approach, survival
1995
12
(54.5%)
27.3%(6/22)

10

3

2002

(45.4%)
(31.8%)

12

22

61
13.6% (3/22)
(81.8%)
(13.6%)

50%(11/22)
(18.1%)

9.1% (2/23)

(81.9%)

Address for reprints: Dr. KW Lam
Department of Cardiothoracic Surgery, Queen Elizabeth
Hospital, Kowloon
Fax: (852) 2958 6875
Received December 17, 2003; revision accepted February 4, 2004

J HK Coll Cardiol, Vol 12

January/April 2004

7

SURGERY FOR CARDIAC TUMORS (PRIMARY AND SECONDARY)

101.4

813 ml

2

40

3

3 4

2 5

Introduction
Primary cardiac tumor is rare entities.1 Three
quarters of tumor are benign and nearly half of the
benign tumors are myxoma. Metastatic tumor
component, on the other hand, is relatively frequent. It
is generally located in the pericardium.1 Diagnosis is
usually difficult since clinical manifestations varied and
sometimes patients may be asymptomatic. Surgical
results in patients with primary cardiac tumors depend
upon the anatomical and histological type of tumors.
Conduction disturbances and supra-ventricular
arrhythmias are common complications following
excision of left atrial myxomas. Superior-septal
approach can injure sinus node function because incision
interrupts the sinus node artery.2 Benign cardiac tumors
are generally curable if surgically excised, and the
prognosis is excellent. Aggressive surgery can palliate
obstructive symptoms in malignant tumors and allow
time for adjuvant therapy even though it may result in
incomplete excision.3

Patients and Methods
Cardiac tumors (primary and secondary) were
resected from 22 patients in Queen Elizabeth Hospital
between the period of March 1995-December 2002.
There were 12 male (54.5%) and 10 female (45.5%)
patients (age between 14-72). Median age was 61 and
mean age was 56.7.
Tumors were mainly divided into 3 groups:
primary (benign and malignant), secondary (metastatic)
and mediastinal tumor with cardiac invasion. Primary,

8

4 8 . 6

1

3

8

1

6

benign cardiac tumor, myxoma (n=11), accounted for
50% of all cases. Primary malignant composed of 9%
of all cases. One of them was angiosarcoma (n=1) and
the other malignant fibrous histiocytoma (n=1). Of the
secondary cardiac tumors, 3 were metastasis from
carcinoma of lung (13.6%), including one large cell
carcinoma and 2 non-small cell carcinoma. In the
remaining cases, 2 were metastasis from the liver
(hepatocellular carcinoma) and one from the bladder
(transitional cell carcinoma). Lastly, the mediastinal
group with cardiac invasion accounted for 13.6%, of
all which 2 were malignant thymoma (n=2) and one
germ cell tumor (n=1) (Tables 1 & 2).

Presenting Symptom
The majority (81.8%) of patients presented with
shortness of breath and chest pain (31.8%). Embolic
events (including recurrent TIA and pulmonary
embolus) were noted in 3 patients (13.6%). One of the
pulmonary embolus was located in the right pulmonary
artery with extension into the right ventricle. Three of
the patients presented with Superior Vena Caval
Obstruction (SVCO) syndrome. Various cardiopulmonary symptoms (including dizziness, cough,
hemoptysis and fever) had been reported (Table 3).

Investigation
All patients had echocardiogram (transthoracic)
as their diagnostic modalities. Transoesophageal
echocardiogram and CT thorax were performed in

January/April 2004
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Table 1. Results (primary cardiac tumor)
Lesion
Myxoma
Malignant fibrous histiocytoma
Angiosarcoma
LA: left atrium; RA: right atrium

No
11
1
1

(benign)
(malignant)
(malignant)

Sex (M/F)
3/8
0/1
1/0

Site
LA (2), interatrial septum (9)
LA
RA

Table 2. Results (secondary / metastasis)
Lesion
Mediastinal

No
2
1

Sex (M/F)
2/0
1/0

Site
Thymoma / thymic CA
Thymus
Germ cell
Mediastinal with bilateral pleural extension, right
bronchus and trachea
Secondary
HCC
2
2/0
RV, IVC
TCC
1
1/0
RA
Lung CA
3
2/1
RV, LA, RVOT
CA: cancer; HCC: hepatocellular carcinoma; TCC: transitional cell carinoma; RV: right ventricle; IVC: inferior vena cava; RA:
right atrium, AV: atrio-ventricular; RVOT: right ventricular outflow tract

Table 3. Clinical presentations
Symptom
Dyspnea
CHF
Chest pain
Syncope
Embolism

Cerebral
Peripheral
Coronary
AII 3

Myxoma
8/11 (72.7%)
4/11 (36.3%)
5/11 (45.4%)
0
1/11 (9.09%)
0
1/11 (9.09%)

Primary malignant
2/2 (100%)
1/2 (50%)
1/2 (50%)
0
0
0
0
0
1 (hemoptysis)

Constitional
3/11 (27.2%)
manifestation
SVCO
0
0
CHF: congestive heart failure; SVCO: superior vena caval obstruction

selected patients. One patient with history of ischemic
heart disease also had coronary angiogram as part of
the preoperative investigation (Figure 1).
Tumor size range from 2.5 x 5 cm to 7-8 cm x 5.5
cm in size. Of all the atrial myxoma, 4 had narrow stalk
and one was pedicled. Two had broad sessile base. For
the non-myxomatous tumor group, only one of them

J HK Coll Cardiol, Vol 12

Secondary malignant
5/6 (83.3%)
1/6 (16.7%)
1/6 (16.7%)
0
0
2/6 (33.3%)
0
0
0

Mediastinal tumor
3/3 (100%)
0
0
0
0
0
0
0
0

0

3/3 (100%)

had narrow stalk. One patient had tumor arising from
the pulmonary valve annulus (Figures 2 & 3).
In each case, tumor was excised during total
cardiopulmonary bypass under moderate hypothermia.
The average cross-clamp time and bypass time were
48.6 minutes and 101.4 minutes respectively. The
average blood loss was 813 ml.
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Tumor size: range from 2.5 x 5 cm to 7-8 cm x 5.5 cm in size
(echocardiogram)

Surgical approaches were mainly accessed via
the right atrium (right atriotomy). Amongst these 17
cases, superior-septal approach was employed in 6 of
the cases. Trans-septal approach was used in 3 cases.
One of them required the extension of incision into the
left atrium. Another required incision into pulmonary
artery because of the extent of the tumor mass.
Tumor excision was performed in 17 cases and
the remaining 5 were performed as palliative procedures
(Figures 4 & 5).
Excision of the atrial tumor with an adequate
margin was generally performed in each of these cases.
Atrial septal defect (ASD) was created in 5 of these
cases, in which 2 of them required patch repair. Primary
closure (of ASD) was performed in the remaining case.
One patient also had co-existing mitral valve
replacement (Figure 6 & Table 4).

Figure 1. Diagnostic modalities.

Figure 2. Morphology of tumor masses.

10
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Figure 3. Site and distribution of tumor.

Figure 4. Surgical procedures.

Figure 5. Surgical approaches.
J HK Coll Cardiol, Vol 12
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Figure 6. Type of surgery (treatment group: tumor excision).

bleeding. The third patient with angiosarcoma died
of multi-organ failure and sepsis (due to the rapid
progression of the disease) (Table 5).
Recurrence had been reported in 2 patients.
One with malignant fibrous histiocytoma and large
cell carcinoma (lung), in which both received cycles
of chemotherapy. The tumor size were large and in
conjunction with its aggressive nature and rapid
growth, debulking surgery had been performed for
palliative purposes.

Table 4. Early morbidity
• Cardiac complications
- Junctional bradycardia
- Pericardial effusion
• Respiratory complications
- Pneumonia
• Thoracic complications
- SVCO obstruction
- Bilateral diaphagmatic paralysis
• Systemic complications
- Secondary hemorrhage
- Wound infection
- Sepsis
- GI bleeding
- Hypoxic brain damage
- Multi-organ failure/DIC
- Embolic events

2
1
1
1
1
1
1
1
2
1
1
1

Follow up
All 12 survivors (10 myxoma, 1 thymic
carcinoma and 1 malignant thymoma) remained
asymptomatic during the time of follow-up of up to
7 years. One patient with germ cell tumor was lost to
follow-up.

Early Deaths
Early deaths were defined as death within 30
days of operation which occurred in 3 of our patients.
One of them (with secondary metastasis from
transitional cell carcinoma) died of complications as
a result of tumor obstruction to the right ventricular
outflow tract. The second patient (carcinoma of
unknown origin, ? lung) died of gastrointestinal

12

Discussion
Tumors of the heart remain a rare occurrence.
The incidence of primary cardiac neoplasia ranges
from 0.001% to 0.03% in autopsy report.4
In adult, approximately 75% of such tumors
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Table 5. Late deaths
Tumor type

Sex/age

Large cell carcinoma
HCC

M/58
M/62

Time from presentation
till death
5 months
6 months

HCC
MFH

M/62
F/64

6 months
2 years

Evidence of recurrence

Cause of death

Malignant pleural effusion
(FU PWH)

Large cell CA
Palliative resection of
tumor (RVOTO)
Progression of RHF
HCC, RHF
Progression of CHF
Disseminated CA

Palliative resection of tumor
Yes (LA wall with
obstruction to MV valve
prosthesis)
Secondary cell
M/59
3 years
Intraperitoneal metastatic
CA lung
carcinoma (lung)
spread
Myxoma
F/59
3 years
Emboli (recurrent TIA,
Sepsis, MOF
(background history
popliteal and femoral artery
of CA breast)
thrombosis) septic
encephalopathy
CA: cancer; HCC: hepatocellular; MFH: malignant fibroblastic histiocytoma; RHF: right heart failure; CHF: congestive heart
failure; TIA: transient ischemic attack; MOF: multi-organ failure

are benign and 25% are malignant.5 Eleven of 22 (50%)
tumors in this surgical series were benign tumor and
all were myxoma. Two (9.1%) were primary
malignant tumors (Figure 1). In the remaining 8 cases
were metastatic tumor (arising from lung, liver and
bladder). 3/22 (13.6%) were mediastinal tumor with
cardiac invasion (Figure 2).
Myxoma is the most common primary tumor
of the heart (30-50% of all cases). They may affect
patients of all ages, predominantly women. They are
gelatinous masses (myxomatous), lobulated, attached
to the endocardium via a variable sized pedicle or by
a wide base that project toward the interior of the
cavity without infiltrating the underlying tissue. 7580% are found in the left atrium, especially associated
to the fossa ovalis.3
Sarcoma accounted for almost all these
malignant tumors, they have a rapid and fatal
evolution. Surgical statistics show that the most
frequent malignant tumors are angiosarcoma (3540%), most of which (80%) are located in the right
atrium.1 They are invasive tumor masses, with areas
of necrosis and hemorrhage affecting the
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myocardium, and may protrude into the atrial cavity.
Because of its unique location, they can manifest as
right heart failure. Pericardial effusion (usually
hemorrhagic in nature with or without tamponade)
as well as systemic manifestation (e.g. fever, weight
loss) had also been reported in the literature.1
The only patient with angiosarcoma (primary
malignant) in our series, the tumor was also sited in
the right atrium. He presented acutely with marked
shortness of breath and hemoptysis. His condition
deteriorated rapidly despite palliative surgical
resection of the tumor. He went on to develop multiorgan failure, septicaemic shock and eventfully died
the next day after surgery.
Secondary cardiac neoplasms are 20-40 times
more common compared with primary malignancies.3
Metastases can reach the heart via blood stream and
coronary arteries (e.g. melanoma, sarcoma and
bronchogenic carcinoma). Other routes include the
lymphatic channels or direct invasion of tumor from
adjacent lung, breast, oesophagus and thymus.
Pericardium is the most frequently involved structure
through direct invasion by various thoracic tumors.
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Clinical symptoms were commonly reported to
be found in 10% of these patients6 Pericardial effusion
or cardiac tamponade was the most common symptom.
Three of our patients (with mediastinal tumor) presented
with symptoms of superior vena cava obstruction.
Abdominal and pelvic tumors may grow in a
cephalad direction via the inferior vena cava to reach
the right atrium. Up to ~10% of cases of renal cell
carcinoma behave in this manner and nearly 40% of
these reach the right atrium.3

Surgical Approaches
Various approaches had been described in the
literature, depending on the site and extent of tumor
involvement. The superior-septal approach (SS) had
been adopted in the majority of the cases, however,
trans-septal approach (TS) had also been used
depending on the location of the tumor.
The proposed advantages of TS include only
one atrial incision, adequate exposure for evaluation
of the mitral valve, low recurrence rates and its long
term efficacy. 7 The SS, on the other hand, provides
an excellent exposure for en bloc removal of the
tumor with simultaneous visualization of both sides
(right and left) of the inter-atrial septum. It is
associated with a lower risk of damaging the mass
and thus tumor embolisation.
Supra-ventricular arrhythmias and conduction
disturbances were commonly reported following this
approach, as the sinus nodal artery is often interrupted
during the incision and thus sinus nodal function.2
In our series, 3 cases of post-operative
arrhythmia had been reported. Two of them were
junctional bradycardia and the SS approach had been
adopted in these cases. One required temporary
pacing which subsequently self-reverted to sinus
rhythm. The third patient had complete heart block
prior to operation (likely relating to tumor invasion
of the conduction system), she sustained such rhythm
post-operatively, which lately required permanent
pacing for treatment of her condition. The prognosis
for resection of atrial myxoma, as repetitively
reported in the literature, has been excellent. The
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optimal operative approach lacks uniformity. There
is still considerable controversy concerning the extent
of surgical resection necessary to prevent recurrence.5
The rate of recurrence had been reported to be
between 4-7% in different series.5,8 In our series, only
one patient with myxoma died 3 years after surgical
treatment. She suffered from complications
(including septic encephalopathy and multi-organ
failure) likely relating to her past history of breast
cancer. During the course of her follow-up, there had
been no evidence of recurrence of myxoma.
Post-operative echocardiogram had been
generally recommended to detect recurrence. Except
for those patients with multiple, atypical or familial
myxoma, few trans-thoracic echocardiogram at 5year intervals throughout life should be adequate if
there has been recurrence in the first few years.9
On the other hand, prognosis is generally poor
in those with primary malignant or secondary
neoplasms. Surgical treatment is directed at providing
symptomatic relief with minimal patient discomfort
and hospital stay. 3 All patients with secondary
neoplasms died after a period of follow-up ranging
between 3 months to 3 years.
In conclusion, surgical resection, when
possible, is the treatment of choice for all patients
with cardiac neoplasms. It is curative in benign
tumors. Palliative procedures, on the other hand, may
be carried out for malignant tumors for relief of
obstructive symptoms. It may prolong life and allow
time for effective adjuvant therapy, but this would
depend on the histological type (thus natural behavior
of the tumor) and the location of the lesion.
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Impact of a Multidisciplinary Heart Failure Management
Programme on Clinical Outcomes and Hospital Admissions
TAT-CHI LEUNG,1 CHUNG-TAI SY,1 MAY SHUK-MAI LAM,1 KAM-WAH WONG,2 SAI-HO DAI,3 PUI-YEE
LAW,4 SHU-KIN LI1
From 1Department of Medicine, 2Department of Physiotherapy, 3Department of Occupational Therapy, 4Department
of Dietetic, Pamela Youde Nethersole Eastern Hospital, Hong Kong
LEUNG ET AL.: Impact of a Multidisciplinary Heart Failure Management Programme on Clinical Outcomes
and Hospital Admissions. Objectives: Heart failure is associated with significant morbidity and high admission
rate. We evaluated the impact of a multidisciplinary heart failure management programme in a regional hospital.
Methods: From March 2001 to January 2003, fourteen patients with heart failure and history of ≥1 hospitalization
for heart failure in the previous 6 months were recruited. Patients attended the programme twice per week for
3 months. Patients were cared by a multidisciplinary team including cardiologist, geriatrician, registered nurse,
physiotherapist, occupational therapist and dietitian. All patients were counseled on different aspects about heart
failure and received exercise training. Medications for heart failure were optimized. Knowledge of the disease, drug
compliance, functional class, exercise capacity and quality of life were assessed before and after the programme.
Number of heart failure hospitalization and the cost of care within the 6 months before enrolment were compared to
that within the 6 months after enrolment. Results: The number of hospitalization for heart failure was reduced
significantly from 28 to 6 (a reduction of 78.6%, p<0.001). Knowledge score, drug compliance score, New York
Heart Association (NYHA) class, 6-minute walk and quality of life scores all improved significantly. An estimated
cost saving of HK$11,340 per patient was achieved over a 6-month time frame (reduction of in-patient costs by
HK$35,880 per patient and an increase in outpatient costs by HK$24,540 per patient). Conclusions: Multidisciplinary
heart failure management programme is feasible in our locality. It can improve clinical outcomes; reduce heart
failure hospitalizations and the high cost burden of this condition. (J HK Coll Cardiol 2004;12:16-22)
Cardiac rehabilitation, exercise, heart failure, multidisciplinary approach
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Background
Heart failure is a growing public health problem
in Hong Kong and in many other countries. Both the
incidence and the prevalence of chronic heart failure
are increasing. Heart failure is associated with poor
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prognosis, reduced quality of life and is one the most
significant causes of hospital admissions. In the United
States, the incidence of heart failure approaches 10%
per 1,000 population after age 65.1 Heart failure accounts
for 5 to 10% of all hospitalizations in the United States
annually, and is the leading cause of hospitalization in
individuals older than 65 years of age. Hospital
discharges for heart failure increased for more than three
times from 1979 to 1997. Readmission rate for
congestive heart failure is very high, with half of the
patients readmitted within 6 months.2,3 In Hong Kong,
heart failure is also an important cause of hospital
admissions.4 The overall incidence was 0.7 per 1,000
population, whereas in the older than 85-year age group,
the incidence was 20 per 1000 women and 14 per 1,000
men.5 Cost of care for heart failure is very substantial
because of the high hospitalization and rehospitalization
rate. In the United States, heart failure costs about
US$38 billion annually, of which approximately twothirds of this amount are spent on hospitalizations.6,7
Non-compliance to optimal pharmacological,
dietary or physical activity regimens is a major cause
for heart failure decompensation.8 It has been shown
that early re-hospitalization in patients with heart failure
may be preventable in up to 50% of cases.2,9,10 These
preventable negative factors include noncompliance
with medications or diet, inadequate discharge planning
or follow-up, and failure to seek medical attention
promptly when symptoms recur. Recent studies have
shown that multidisciplinary heart failure disease
management programme can improve the clinical
outcomes and quality of life of patients with heart
failure, and reduce hospital admissions and resources
utilization.11-18
We designed and implemented a multidisciplinary management programme for heart failure
patients in our hospital to determine whether this kind
of programme is feasible and beneficial in our locality.
The objectives of the programme were to optimize the
medications; to improve the quality of life, compliance,
symptoms, and functional status of patients with heart
failure; to decrease the hospital admissions and cost
of care for heart failure through multidisciplinary
management approach.
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Methods
Patient Selection
From March 2001 to January 2003, patients
admitted to Pamela Youde Nethersole Eastern Hospital
with a primary diagnosis of congestive heart failure were
screened for enrolment. The inclusion criteria were: age
>18; moderate to severe symptomatic heart failure
(NYHA Class II to IV); history of 1 or more than
1 hospitalization for heart failure in the previous
6 months.
The criteria for exclusion from the study
included: acute myocardial infarction within 4 weeks
of entry; unstable coronary artery disease, acute
myocarditis, constrictive pericarditis and other
significant co-morbid conditions such as dementia
or malignancy that likely to limit compliance or
survival.

Baseline Evaluation and Outcome Measurement
Baseline evaluation included a history and
physical examination performed by a cardiologist.
Echocardiography was performed to assess the left
ventricular function if it had not been performed in the
previous six months.
Each patient was his/her own control and a
comparison was made before and after the intervention.
Data were obtained at entry to the study and at the end
of the programme. Assessments included knowledge
of the disease; drug compliance; sodium intake; New
York Heart Association Class; exercise capacity
measured by 6-minute walk test; quality of life using
the Minnesota Living with Heart Failure Questionnaire.19
Sodium intake was assessed using a food frequency
questionnaire. Each participant was interviewed by a
dietitian with respect to food portion size, intake of food
containing sodium, frequency of intake per week and
month. Hospital diet was used as a reference to sodium
level of seasoning. Average daily sodium intake was
calculated based on the nutrient database of Nutritional
Five (First DataBank Inc., 1998) and commercial food
labeling. Knowledge of the disease was assessed by a
set of 21 questions designed by our team, regarding the
symptoms and worsening symptoms of heart failure;
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the proper diet and physical activities. Drug compliance
was assessed by asking the patients 6 questions
regarding the name, dosage, frequency, route of
administration and side effects of the medications for
heart failure.
Number of heart failure hospitalization within the
6 months before enrolment was compared to that within
the 6 months after enrolment. Death and other
significant morbidity were also recorded.
Medications usage and dose were recorded at
baseline and at end of the programme. Angiotensin
converting enzyme inhibitors (ACE-I) were grouped and
ranked according to dose: 'low dose' ≤10 mg/day of
lisinopril or equivalent, 'medium dose' 10 to <20 mg/
day lisinopril or equivalent; and 'high dose' ≥20 mg/
day lisinopril or equivalent. Similarly, beta-blockers
were also ranked according to dose: 'low dose' ≤12.5
mg/day carvedilol or equivalent; 'medium dose' 12.5 to
<50 mg/day carvedilol or equivalent; 'high dose' ≥50
mg/day carvedilol or equivalent.

nurse on different aspects of heart failure with emphasis
on warning symptoms and signs of deterioration; and
the importance of daily weighing. Each patient also
received an educational booklet on heart failure. Patients
and their caretaker received advice from the dietitian
regarding diet, fluid and sodium management. Energy
conservation technique, work simplification advice and
relaxation practice were given by the occupational
therapist.
All patients were assessed individually by the
physiotherapist and received exercise training designed
for heart failure patients. The exercise programme lasted
for 3 months, two times per week. It included a
combined programme of treadmill exercise, static bike
riding and upper limb ergometer training. Patients were
exercised to a heart rate of 50-60% of maximum
predicted for age and a Borg rating of 9-12 for perceived
exertion. Patients were encouraged to maintain a home
programme of daily walking for a total period of
exercise 30-minute per day, 5-7 days per week.

Multidisciplinary Management Programme

Statistical Method

Patients attended the programme twice per week
for about 3 months which took place at the Day Hospital
of the Pamela Youde Nethersole Eastern Hospital.
Patients were cared by a multidisciplinary team. The
team included a cardiologist, a geriatrician, a registered
nurse, a physiotherapist, an occupational therapist and
a dietitian.
Each patient received an initial consultation with
the cardiologist or the geriatrician. This was a
comprehensive assessment of the patient's heart failure
status. A monthly conference was held to discuss the
progress of the patients. Followed-up review by
physician would be arranged if required.
Medications for heart failure, especially
angiotensin converting enzyme inhibitors and betablockers were optimized according to the ACC/AHA
heart failure management guideline.20 The side effect
and the importance of drug treatment were emphasized.
Instructions on the use of a flexible diuretic regimen
and dosage adjustment in response to worsening
symptoms and weight change were given.
All patients were counseled by the registered

The baseline demographic data were expressed
as mean and standard deviation. The changes between
the data obtained before and after the programme were
analyzed using paired t-test. A p-value less than 0.05
was considered to be statistically significant. Analyses
were performed using SPSS (version 10.0).
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Results
Patient Population
From March 2001 to January 2003, fourteen
patients with heart failure and history of ≥1
hospitalization for heart failure in the previous 6 months
were recruited. The mean age was 71.9±5.9 (range 6184). The male to female ratio was 1:1. The mean ejection
fraction was 38.5±15.0%. Most patients were in NYHA
Class III (71.4%), 21.4% of patients in Class II and
7.1% in Class IV. The etiology of heart failure were:
ischemic cardiomyopathy (50%), dilated
cardiomyopathy (14.2%), hypertensive heart disease
(21.4%) and valvular heart disease (14.2%). All
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patients completed the programme. No patient died
during follow-up up to 6 months.

Hospitalizations (Figure 1)
Hospitalizations were significantly reduced. In
the 6 months prior to the start of the programme, the
total number of hospitalizations for heart failure was
28. The mean number of hospitalizations for heart
failure per patient was 2.0. In the 6 months after
enrollment to the programme, the total number of
hospitalizations for heart failure was 6. The mean
number of hospitalizations per patient was 0.43.
Hospitalization for heart failure was reduced by 78.5%
(p<0.001). Bed days were significantly reduced from a
total of 362 days (of which 177 were acute bed days,
185 were convalescent bed days) to 165 days following
the programme (of which 15 were acute bed days and
150 were convalescent bed days) (p<0.001). Outpatient
clinic attendance also reduced from 34 to 24 following
the programme.

Drug Therapies
At baseline, 71.4% of patients were receiving
ACE-I or angiotensin receptor blocker (ARB), 70% or
them were receiving high dose. At the end of the
programme, 78.8% were receiving ACE-I or ARB and

21.4% of patients had a dose increment from their
baseline dose. Regarding beta-blockers, 35.7% of
patients were taking them at baseline: 60% were on low
dose; 40% on medium dose; and none on high dose. At
follow-up, 50% of patients were on beta-blockers of
whom 14.3% were on low dose; 57.1% were on medium
dose and 28.6% were on high dose and 35.7% of study
patients had a dose increment.

Functional Status and Quality of Life (Table 1)
A significant improvement in symptoms and
functional status was found. The NYHA Class improved
from 2.9±0.6 at baseline to 1.7±0.4 at follow-up (p<0.001).
Exercise capacity as measured by 6-min walk test also
improved from a mean of 289.3±67.5 meters to 339.1
±67.8 meters (p=0.005). Quality of life improved
significantly after the programme. The Minnesota
Living with Heart Failure Questionnaires improved
from a score of 39.4±7.6 to 16.4±10.4 following the
programme (p=0.001).

Knowledge, Drug Compliance and Sodium
Intake (Table 1)
Both the knowledge of the disease and drug
compliance improved after the programme. The
knowledge score improved from 19.9±1.5 at baseline

Figure 1. Total number of hospital admissions for heart failure in the 6 months before and
after the programme (reduction of 78.6%, p<0.001).
J HK Coll Cardiol, Vol 12
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to 22.8±1.6 (p<0.001) at follow-up. The drug
compliance score improved from 3.9±0.2 to 5.7±0.5
(p=0.001). The estimated daily sodium intake was 3.4 g
and 3.3 g before and after the programme respectively
(p: n.s.).

Costs (Table 2)
The cost of care for different modalities were
calculated by the finance department of our hospital,
using the specialty costing exercise model and taking
into account of the labour cost of different disciplines,
cost for drugs and equipment. The average cost per bed
day for acute bed was HK$2,662 and for convalescent
bed was HK$2,031. The average cost per out-patient
clinic attendance was HK$1,024 and per visit to the
programme (Day Hospital visit) was HK$1,404.
Comparing the cost of care in the 6 months prior the
programme with that spent in the 6 months following
enrolment, there was a reduction of inpatient costs by
HK$35,880 per patient and an increase in outpatient
costs by HK$24,540 per patient. An estimated cost
saving of HK$11,340 per patient over a 6-month time
frame was achieved.

Discussion
There is growing evidence in supporting a multidisciplinary management approach to patients with
chronic heart failure.11-18 Increasing input into outpatient
care can reduce expensive hospital readmissions. Based
on available evidence, it is appropriate to recommend
widespread development and application of
multidisciplinary heart failure disease management. Our
study, although involved only a small number of
patients, demonstrated that multidisciplinary heart
failure disease program is effective in reducing hospital
admissions, hospital days and cost of care; enhancing
patient knowledge and compliance with medications;
improving functional capacity and quality of life. The
only non-significant finding in our study was the
estimated daily salt intake before and after the
intervention.
Drug therapies, especially ACE-I and betablockers, have been shown to improve survival and
reduce hospitalizations in patients with heart failure.
Optimization of drug therapies was one of the objectives
of our programme. We observed that by the end of the

Table 1. Summary of the effects of the multidisciplinary heart failure programme
Pre-programme
2.9±0.6
289.3±67.5
39.4±17.6
19.9±1.5
3.9±0.2
3.4

NYHA Class
6-minute walk (meters)
Quality of life (Minnesota HF questionnaire 0-105)
Knowledge score (0-21)
Drug compliance score (0-6)
Estimated daily sodium intake (gram)

Post-programme
1.7±0.4
339.1±67.8
16.4±10.4
22.8±1.6
5.7±0.5
3.3

p-value
<0.001
0.005
0.001
<0.001
0.001
n.s.

Table 2. Comparison of resource utilizations and cost of care per patient in the 6 months before and after the
programme

Acute bed days
Convalescent bed days
Outpatient clinic visit
Day hospital visit
Cost savings (Total)

20

Pre-programme number /
Cost (HK$)
177 / 33,655
185 / 26,838
34 / 2,487
2 / 201
-----

Post programme number /
Cost (HK$)
15 / 2,852
150 / 21,761
24 / 1,755
254 / 25,473
-----

January/April 2004

Cost savings
(HK$)
30,803
5,077
732
-25,272
11,340
(p<0.001)
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study, the usage of ACE-I and beta-blockers were
improved. We believed that the improvement in various
parameters after intervention in our study could be partly
contributed by a better medical regimen. However, the
improvement was unlikely to be related entirely to the
introduction and up-titration of medical treatment,
because patients who could not tolerate beta-blocker
still demonstrated no hospitalizations in the follow-up
period.
Most published trials were done at academic
centre in other countries while non-academic centres
may lack the necessary facilities and personnel to
assemble an effective heart failure management team.
Our study demonstrated that this kind of multidisciplinary programme is feasible in our locality and
could be implemented in a regional hospital. It is
necessary, before implementing the programme, to
consider a variety of disease management models, to
select and modify the model most suited to a given
practice environment because a single, unified approach
is unlikely to be applicable to different practice settings.

Lastly, the programme was multidisciplinary and
the relative contributions of its various components
could not be assessed. Future studies are needed to
determine the relative merits of each component of the
programme.

Conclusions
This is one of the first studies to assess a
comprehensive multidisciplinary management
programme specific to heart failure in our locality. Our
study showed that a multidisciplinary approach with
intensive outpatient care improves patient outcomes,
reduces heart failure admissions and the high cost
burden of this disease. Such management could be
implemented in our locality and may become the
standard care for heart failure patients, especially those
with high risk of admission.
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Letter to the Editor
Electron Beam Computed Tomography
Dear Editor,
The ability of Electron Beam Computer
Tomography (EBT) to detect presence of coronary
calcification in asymptomatic patients has fueled much
debate regarding the appropriate use of this new imaging
modality.
It is apparent that the extent of calcification, in
terms of both an absolute volume and an age related
percentile score, is predictive of relative risk of coronary
artery events. It has also been demonstrated that risk
stratification by Coronary Calcium Scoring has
incremental value over "traditional risk assessment". As
Dr. Rumberger correctly points out: certain basic
epidemiological characteristics of EBT have been
defined (there is a low absolute risk of coronary artery
disease (CAD) with a zero coronary calcium score,
increased relative risk of events and increased likelihood
of angiographically significant CAD occurs with high
scores).
The source of the real debate is not these issues,
but rather whether and how this test should be
incorporated into routine clinical cardiology practice.
Firstly, should the test be used as a non-invasive test in
selected populations with intermediate risk of CAD or
as a screening test for the early detection of
atherosclerosis in unselected populations?
There are numerous factors regarding clinical
application of coronary calcium scoring that remain
undefined:

2.

3.
4.

1. How should the results of EBT influence the level
of aggressiveness of medical therapy in
asymptomatic patients? For instance:
5.
Opinions expressed are views of the authors and not necessarily
the view of the editorial board or the Hong Kong College of
Cardiology.
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a) Should a patient with a zero score continue with
standard primary prevention risk factor
modification? Are we doing these people an
injustice by providing false reassurance with a
"zero" score?
b) Does presence of any coronary calcium in an
asymptomatic patient indicate the need to move
to aggressive (secondary style) risk factor
modification? Should these patients be prescribed
aspirin?
c) What is the evidence that asymptomatic patients
with coronary calcium scores >75% for age
actually benefit from further investigations such
as stress testing? Although higher scores may be
associated with increased atherosclerotic burden,
what percentage of these patients actually have
inducible ischemia at stress testing? Preliminary
reports would suggest this percentage is low
unless the total calcium burden (Agatson score)
is greater than 400.1
What is the utility of serial coronary artery calcium
testing, particularly after initiation of medical
therapy? What do you say to a patient who has been
compliant with statin therapy but has multiple new
calcified lesions at follow up?
Is there a role for EBT in patients with prior
revascularization?
Where should EBT be placed in the testing algorithm
for symptomatic patients? Given that the risk of acute
events relates to unstable plaque, and risk
stratification in the presence of known coronary
artery disease has been shown to relate to the extent
of inducible ischemia and left ventricular function
is knowledge of the coronary calcium burden
additive or simply redundant information?
Numerous characteristics of plaque that has been
shown to relate to risk of plaque rupture cannot be
assessed by electronic beam computer tomography
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(i.e. plaque ulceration and surface contour, fibrous
cap, lipid content etc.). Given that a relatively small
amount of the total atherosclerotic plaque burden is
calcified plaque, the relationship between coronary
calcium scores and risk of acute events must be more
variable than Dr. Rumberger suggests. Testing for
plaque stability is the ideal approach and should be
incorporated into plaque imaging.
6. Most importantly, there is no information available
to date regarding the cost implications of coronary
artery calcium assessment in testing strategies for
symptomatic or asymptomatic patients in low or
intermediate risk groups. Calcium scoring has the
potential to generate considerable downstream costs
from non-invasive and invasive evaluations, or from
altered medical management strategies.
We agree with Dr. Rumberger that an extensive
literature exists validating that physiologically the
presence of coronary calcium has meaning. We also
agree that "coronary artery disease" can be defined today
either as the presence of a significant epicardial stenosis
(a traditional angiographic definition) or as the presence
of atherosclerosis as demonstrated by detection of
coronary artery plaque with or without associated
calcification. As pointed out by Dr. Rumberger,
electronic beam computer tomography is far superior
for identification of calcified plaque than for the
detection of patients with angiographically significant
stenosis.
Hence, as alluded to by Dr. Rumberger, despite
early claims that EBT would serve as a test to replace
conventional stress imaging, in light of its performance
characteristics this is unlikely to be the case. Rather,
EBT is one of a number of tests currently available to
clinicians for identification of the presence of preclinical
atherosclerosis (e.g. EBT, Intimal Medial Thickening,
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Ankle Brachial Index). In addition, there are an
increasing number of biochemical markers (such as high
sensitivity C-reactive Protein) gaining acceptance for
their ability to identify asymptomatic patients at risk of
adverse cardiac events.
The questions facing cardiologists today are
which combination of tests should be obtained in
clinical practice to identify those asymptomatic
patients at risk of events secondary to premature
atherosclerosis. And in the event of symptoms, which
combination of tests most accurately and efficiently
leads to diagnosis, risk stratification and formulation
of a management plan. EBT may well play an
important role as a component of an algorithm in the
future. However, this will only be the case after more
extensive data is collected validating it's performance
characteristics both individually and as part of a
testing algorithm.
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